 |
|
|
| |
Fatty Liver / NASH at EASL
|
| |
| |
from Jules: here are reports on fatty liver and NASH including key reports from EASL on fatty liver & NASH with more reports coming. In HIV fatty liver & NASH are often overlooked and not at all considered. An HIV_ person may have fatty liver and or NASH but the clinician may nor be aware that the patient could have this condition. The same is true outside of HIV - the possibility that a person may have fatty liver is often not even considered because its not on the radar. In HIV what often happens is a patient may have elevated liver enzymes - ALT, AST - but the doctor or clinician does not understand that this could be due to fatty liver and NASH. Up until treatment & diagnosis have not been very effective although diet & exercise are cornerstones, but research is gearing up to find effective treatments.
In the United States, studies report a prevalence of NAFLD of 10 to 46 percent, with most biopsy-based studies reporting a prevalence of NASH of 3 to 5 percent. Worldwide, NAFLD has a reported prevalence of 6 to 35 percent (median 20 percent). NHANES reports that NAFLD affects 18% of obese adolescents with no metabolic abnormality "indicating that obesity and excess visceral adiposity are independently associated with increased risk of NAFLD in adolescents regardless of metabolic derangements. The major risk factors for hepatic fat and hepatic fibrosis development in NAFLD are well established - age >50 years, obesity, insulin resistance, type 2 diabetes. Significant & increasing healthcare costs are associated with fatty liver. Reported at EASL by Stanford group - hospital charges in California - hospital charges over time for patients with fatty liver disease doubled from 2009 to 2013 while remaining stable from 2005 through 2009; cirrhosis accounted for 25% of charges for NAFLD and for cirrhotic patients charges increased; Hispanics accounted for 34% and non Hispanic whites accounted for 50%, and 14% for non white non Hispanic of hospital encounters
EASL: Trends in hospital charges and encounters for patients with nonalcoholic fatty liver disease compared to patients with alcoholic liver disease in the United States between 2005 and 2013 - (06/07/17)
EASL: Incidence and prevalence of recorded non-alcoholic fatty liver disease in four European primary care databases covering 21.9 million adults - (06/02/17)
AASLD/2016: DIAGNOSTIC PATTERN AND DISEASE ACTIVITY ARE RELATED TO DISEASE PROGRESSION AND REGRESSION IN NONALCOHOLIC FATTY LIVER DISEASE - (11/29/16)
Fatty Liver, NAFLD, NASH Definitions - (06/29/17)
Treatment of NAFLD with diet, physical activity and exercise - (05/26/17)
Fatty Liver / NASH - A silent liver disease epidemic - (05/22/17)
Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis - (05/22/17)
EASL: BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: A phase 2 study - (04/24/17)
EASL: Pharmacokinetics of Selonsertib, GS-9674, and/or GS-0976 in Combination in Healthy Subjects - (05/23/17)
EASL: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Suppression of Hepatic De Novo Lipogenesis and Significant Improvements in MRI-PDFF, MRE and Markers of Fibrosis after 12 Weeks of Therapy in Patients with NASH - (05/23/17)
EASL: Treatment with Selonsertib, an Inhibitor of Apoptosis Signal-Regulating Kinase 1 (ASK1), Reduces Hepatic Phospho-p38 Expression and Markers of Hepatocellular Apoptosis and Necrosis in Patients with NASH - (05/23/17)
EASL: Efficacy and Safety of Simtuzumab for the Treatment of NASH with Bridging Fibrosis or Cirrhosis: Results of Two Phase 2b, Dose-Ranging, Randomized, Placebo-Controlled Trials - (05/23/17)
EASL: EDP-305, a novel and highly potent farnesoid X receptor agonist, improves liver steatosis, ballooning and non-alcoholic fatty liver disease (NAFLD) activity score (NAS) in a diet-induced murine model of non-alcoholic steatohepatitis - (05/23/17)
EASL: Enanta Announces New Preclinical Data on its FXR Agonist EDP-305 for Non-Alcoholic Steatohepatitis (NASH) and Primary Biliary Cholangitis (PBC) at The International Liver Congress™ 2017 - (05/23/17)
EASL: A novel farnesoid X receptor agonist: EDP-305, reduces fibrosis progression in animal models of fibrosis - (05/23/17)
EASL: The Novel FXR Agonist, EDP-305, Reduces Fibrosis Progression in Rodent Models of Primary Biliary Cholangitis and Non-alcoholic Steatohepatitis - (05/26/17)
DUR-928, an endogenous regulatory molecule, exhibits anti-inflammatory and antifibrotic activity in a mouse model of NASH - (05/26/17)
Safety and pharmacokinetics of DUR-928 in patients with non-alcoholic steatohepatitis-A Phase 1b study - (05/26/17)
Cenicriviroc Versus Placebo for the Treatment of Nonalcoholic Steatohepatitis with Liver Fibrosis: Results from the Year 1 Primary Analysis of the Phase 2b CENTAUR Study press release http://www.businesswire.com/news/home/20160725005384/en/Tobira-Therapeutics-Announces-Clinically-Statistically-Significant-Improvement
More to come
|
| |
|
|
|
|
|
